Phase II Parallel Arm Study of Sacituzumab Govitecan-Hziy in Patients With Advanced Thymoma or Thymic Carcinoma
- 5 December 2024
- journal article
- research article
- Published by Elsevier in Clinical Lung Cancer
- Vol. 26 (3) , 165-167
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Trop-2 Expression and Its Impact on Survival in Thymic Epithelial Tumors: Brief ReportClinical Lung Cancer, 2024
- High levels of expression of Trop-2 in thymic epithelial tumorsLung Cancer, 2023
- Antibody–Drug Conjugates in Non-Small Cell Lung Cancer: Emergence of a Novel Therapeutic ClassCurrent Oncology Reports, 2022
- Thymic Carcinomas—A Concise Multidisciplinary Update on Recent Developments From the Thymic Carcinoma Working Group of the International Thymic Malignancy Interest GroupJournal of Thoracic Oncology, 2022
- Thymic epithelial tumors: From biology to treatmentCancer Treatment Reviews, 2020
- Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast CancerNew England Journal of Medicine, 2019
- Sacituzumab govitecan (IMMU‐132), an anti‐Trop‐2‐SN‐38 antibody‐drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokineticsCancer, 2017
- Upregulation of Trop-2 quantitatively stimulates human cancer growthOncogene, 2012
- Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from JapanThe Annals of Thoracic Surgery, 2003
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989